TP53 and neoplasm: ctDNA of some tumour suppressors, such as P53 and PTEN, can be detected in all recurrent gliomas, making ctDNA a valuable biomarker for predicting the response to adjuvant therapies, providing real-time information about tumour progression and recurrence.